About & Methodology
Every number on Bharat WorldMeds traces to a named source — official government statistics and publicly available company filings. No estimates, no projections, no surveys.
Bharat WorldMeds is built primarily on official government trade statistics, supplemented by publicly available company filings — not estimates, not projections, not surveys. Every number traces to a source: India's Directorate General of Commercial Intelligence and Statistics (DGCIS), the US Census Bureau, Eurostat, HMRC, Statistics Canada, the Reserve Bank of India, and published annual reports of listed pharmaceutical companies.
| Source | Coverage | Used For |
|---|---|---|
| DGCIS India | FY 2014–15 to 2025–26 | India's pharma exports by destination, HS8 product detail, category mix |
| US Census Bureau | CY 2015–2025 | US imports from India,partner-side headline for US profile |
| Eurostat | CY 2015–2025 | EU member state imports from India |
| HMRC UK | CY 2015–2025 | UK imports from India |
| Statistics Canada | CY 2015–2025 | Canadian imports from India |
| RBI ODI Data | 2011–2026 | Indian pharma overseas direct investment,equity, loans, guarantees |
| US FDA | Current register | FDA-registered manufacturing facilities in India |
| DPIIT India | Cumulative to Q3 FY 2025–26 | Foreign direct investment in Drugs & Pharmaceuticals |
| IP India | 2014–2024 | Pharmaceutical patent filing trends |
Where a destination country publishes its own import data (the "mirror" or "partner" statistics), we show both sides. Partner data often captures shipments that DGCIS misses, and vice versa — dual-source profiles give the most complete picture available.
Fiscal vs. calendar year: DGCIS data follows India's fiscal year (April–March), labelled as the ending year (FY 2025–26 covers April 2025 to March 2026). Partner-country data follows the calendar year. Where both appear on the same profile, the year basis is always labelled.
Product classification: Exports are classified at the product tariff-line level. Products are grouped into five categories: Drug Formulations, Bulk Drugs & APIs, Vaccines, Surgicals, and AYUSH/Herbal — following the standard pharma export taxonomy used by the Pharmaceuticals Export Promotion Council of India (Pharmexcil).
Currency: All trade values are in US dollars. DGCIS originally reports in Indian rupees; we convert using the RBI reference rate for the corresponding month. Partner-country data is reported in USD at source.
Data is updated as source agencies publish — designed for trade policy professionals, industry analysts, and export promotion bodies who need accurate, granular, and current data on India's pharmaceutical trade.
Bharat WorldMeds is an independent publication about India’s pharmaceutical exports. It is not affiliated with, endorsed by, or connected to any other company, pharmacy, or platform with a similar name.
Bharat WorldMeds is not affiliated with, endorsed by, or connected to PhRMA (the Pharmaceutical Research and Manufacturers of America), any government agency, or any pharmaceutical company.
All data is sourced from official government statistical agencies and publicly available company filings as described above. While every effort is made to ensure accuracy, this site provides information for research purposes only and does not constitute trade, investment, or policy advice.
For enquiries, contact: [email protected]